ClinicalTrials.gg
CompletedNCT03779230GLIOMOONUpdated Jun 29, 2023

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

A Phase 1/2 interventional study of L19TNF in Glioma of Brain, sponsored by Philogen S.p.A.. Completed at 3 sites in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Philogen S.p.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.

Read the detailed description

The purpose of this study is to explore the safety and efficacy profile of the antibody-cytokine fusion protein L19TNF in patients with isocitrate dehydrogenase (IDH) wildtype WHO grade III / IV glioma at first relapse

Phase I:

The primary objective of this phase is to evaluate the safety of L19TNF in patients with IDH-wildtype WHO grade III / IV glioma at first relapse and to establish and confirm the recommended dose (RD) for phase II.

Phase II:

The primary objective of this phase is to evaluate antitumor activity of L19TNF in patients with IDH-wildtype WHO grade III / IV glioma at first relapse.

02

Conditions studied

  • Glioma of Brain
03

In context

Lead sponsor

Philogen S.p.A. is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age 18 or more
  2. Patients with confirmed IDH-wildtype WHO grade III / IV glioma at first relapse
  3. Radiographic demonstration of disease progression
  4. Presence of at least one lesion of bi-dimensionally by MRI of at least 1 cm (10 mm) in the longest diameter on baseline MRI.
  5. Performance Score (KPS) ≥ 70%
  6. Documented negative test for --. For HBV serology: the determination of HBsAg, anti-HBsAg-Ab and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  7. Female patients: negative pregnancy test for women of (WOCBP)* within 14 days of starting treatment. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesteron-only or combined (estrogen- and progesteron-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

    Male patients: Male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.

  8. Negative TB test (e.g. Mantoux or Quantiferon assay).
  9. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  10. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures *Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Exclusion criteria

Exclusion Criteria:

  1. Second or later glioma progression.
  2. Surgical resection or of glioma within 4 weeks of the start of study treatment.
  3. Subjects who participated in an drug or device study within 4 weeks prior to study treatment start.
  4. Treatment with tumor-treating fields
  5. Radiotherapy within 6 weeks prior to study treatment start.
  6. Patients unable to undergo contrast-enhanced MRI.
  7. Patient taking herbal medications within 7 days prior to first dose of the study drug.
  8. Known history of allergy to TNF, in study medication or any other intravenously administered human proteins/peptides/antibodies.
  9. (ANC) \< 1.5 x 10\^9/L, \< 100 x 10\^9/L or (Hb) \< 9.0 g/dl.
  10. Chronically impaired renal function as indicated by \< 60 mL/min.
  11. Inadequate liver function (, AST, ALP ≥ 2.5 x or total ≥ 2.0 x ULN)
  12. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
  13. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  14. Heart insufficiency (> Grade II, (NYHA) criteria).
  15. cardiac arrhythmias or requiring permanent medication.
  16. Abnormal or any other abnormalities observed during baseline and echocardiogram investigations that are considered as clinically significant by the investigator.
  17. Uncontrolled hypertension.
  18. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  19. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.
  20. Anxiety ≥ grade 3
  21. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  22. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  23. Pregnancy or breast-feeding.
  24. Requirement of chronic administration of high dose or other drugs. Subjects must have been either off corticosteroids, or on a stable or decreasing dose ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to study treatment start. Limited or occasional use of corticosteroids to treat or prevent acute adverse reactions is not considered an exclusion criterion.
  25. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  26. Concurrent , unless the patient has been disease-free for at least 2 years.
  27. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  28. Serious, non-healing wound, ulcer or bone fracture.
  29. Requirement of concurrent therapy with anticoagulants at therapeutic doses.
  30. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  31. Any recent within 4 weeks prior to treatment or plan to receive vaccination during the study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    L19TNF

    Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.

    Drug: L19TNF

Interventions

  • DrugL19TNF

    Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.

    Also known as: onfekafusp alpha

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicity (DLT)

    Time frame: From the first day of treatment until the end of the DLT window (up to 21 days)

  2. Adverse event (AE), Serious Adverse Events (SAE) and Drug Induced Liver Injury (DILI) assessment based on CTCAE v.5.0

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  3. Standard laboratory (haematology, biochemistry, liver and urine analysis) parameters

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  4. Neurological assessment using the Neurologic assessment in Neuro-Oncology (NANO) scale

    Measurement of neurological function in neuro-oncology

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  5. Karnofsky Performance Status

    Assessment through a questionnaire of symptom-related restriction of activity, self-sufficiency and self-determination

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  6. Electrocardiogram (ECG) findings. In particular, data about QT/QTc intervals will be collected and analysed for QT/QTc prolongation potentially caused by treatment.

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  7. Echocardiogram (ECHO) findings. In particular, data about QT/QTc intervals will be collected and analysed for QT/QTc prolongation potentially caused by treatment.

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  8. Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19TNF.

    Time frame: Cycle 1 day 1 - First Follow Up visit (up to approximately 9 months)

  9. Progression-free survival (PFS), according to iRANO (immunotherapy response assessment in neuro-oncology) criteria based on standardized MRI protocol

    Time frame: At 6 months

Secondary outcomes

  1. Progression free survival (PFS)

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 12 months)

  2. Overall survival (OS).

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 36 months)

  3. Overall Response Rate (ORR, consisting of Complete and partial Response), based on iRANO criteria.

    Time frame: At 12 weeks, 18 weeks, 24 weeks, 36 weeks, 48 weeks

07

Study locations

3 sites
  • Inselspital Bern
    Bern, 3010, Switzerland
  • CHUV Départment d'Oncologie
    Lausanne, CH-1011, Switzerland
  • Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum
    Zürich, CH-8091, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jun 2023, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2018
First posted
Dec 19, 2018
StartActual
May 31, 2019
Primary completionActual
Jun 27, 2023
CompletionActual
Jun 27, 2023
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03779230
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
May 31, 2019
Primary completion
Jun 27, 2023
Completion
Jun 27, 2023
Last update
Jun 29, 2023

Study contacts

Tobias Weiss, MD
principal investigator · Universitätsspital Zürich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onfekafusp alfa

Start the discussion